Syndrome of inappropriate secretion of ADH in the course of chemotherapy for anaplastic large T-cell lymphoma of the lung Opis przypadku

##plugins.themes.bootstrap3.article.main##

Grzegorz Kade
Maciej Michalak
Aleksandra Straszyńska
Dariusz Moczulski
Janusz Hałka
Sebastian Spaleniak

Abstrakt

The present study reports the case of a 40-year-old patient who presented SIADH syndrome due to anaplastic large T-cell lymphoma and antineoplastic drugs.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
1.
Kade G, Michalak M, Straszyńska A, Moczulski D, Hałka J, Spaleniak S. Syndrome of inappropriate secretion of ADH in the course of chemotherapy for anaplastic large T-cell lymphoma of the lung. OncoReview [Internet]. 30 czerwiec 2022 [cytowane 3 lipiec 2024];12(2(46):50-3. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/1965
Dział
ONCOWATCH. PRACTICAL CLINICAL IMAGES

Bibliografia

1. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012; 17(6): 756-65.
2. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2): 239-45.
3. Shepshelovich D, Schechter A, Calvarysky B et al. Medication-induced SIADH: distribution and characterization according to medication class. Br J Clin Pharmacol. 2017; 83(8): 1801-7.
4. Nishiwaki U, Hirata Y, Yokote T et al. Syndrome of inappropriate antidiuretic hormone secretion associated with adult T-cell leukaemia/lymphoma. Br J Haematol. 2014; 166: 155.
5. Harlow PJ, DeClerck YA, Shore NA et al. A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. Cancer. 1979; 44: 896-8.
6. Winiarska K, Taborek M, Czerwieńska B et al. Difficulties in the diagnostics of chronic hyponatremia based on the case study of a 66-year old female patient during antihypertensive therapy. Pol Merkur Lekarski. 2021; 292: 303-5.
7. Matuszkiewicz-Rowińska J., Mieczkowski M. Nefrotoksyczność leków stosowanych w chemioterapii nowotworów. OncoReview. 2012; 2(5): 29-38.

Inne teksty tego samego autora